This study investigates the treatment of pancreatic cancer using an investigational medication alongside gemcitabine and albumin-bound paclitaxel. The purpose of this study is to explore new therapeutic options for this condition.
The study evaluates the safety and effectiveness of this combination treatment. It looks at how patients respond to the treatment and any side effects they may experience.
- Who can participate: Adults aged 18 to 80 with confirmed pancreatic cancer and at least one measurable lesion can participate. Participants must have a performance status of 0 or 1.
- Study details: Participants will receive an investigational medication with other treatments.